This Article Full Text Full Text (PDF) CME: Take the course for this article: Lung Cancer Screening eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ganti, A. K. Articles by Mulshine, J. L. Search for Related Content PubMed PubMed Citation Articles by Ganti, A. K. Articles by Mulshine, J. L.

Lung Cancer

Lung Cancer Screening

^a Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA; ^b Rush University Medical School, Chicago, Illinois, USA

Key Words. Computerized tomographic scans • Spiral CT screening • Lung cancer

Correspondence: Apar Kishor Ganti, M.D., Division of Hematology-Oncology, Department of Internal Medicine, University of Nebraska Medical Center, 987680 Nebraska Medical Center, Omaha, Nebraska 68198-7680, USA. Telephone: 402-559-6210 Fax: 402-559-6520; e-mail: aganti{at}unmc.edu

Advances in imaging technology have ushered in a new era for lung cancer screening in high-risk individuals using computed tomographic (CT) scans. Although most published studies are nonrandomized observational cohorts of volunteers, the ability of CT scans to detect early stage lung cancer is undisputable. What is unresolved is the ability of spiral CT screening to affect lung cancer-related mortality. A large randomized trial sponsored by the National Cancer Institute to address this question is currently under way. Genomic and proteomic approaches promise to complement the ability of spiral CT to detect early lung cancer in the next few years. Currently, the decision to screen for lung cancer should involve a careful discussion with the individuals involved about the potential advantages, costs, and drawbacks of the approach.

This article has been cited by other articles:

				I. M. Burger, N. E. Kass, J. H. Sunshine, and S. S. Siegelman The Use of CT for Screening: A National Survey of Radiologists' Activities and Attitudes Radiology, July 1, 2008; 248(1): 160 - 168. [Abstract] [Full Text] [PDF]

				M.-T. Wu, P. Yang, Y.-L. Huang, J.-S. Chen, C.-C. Chuo, C. Yeh, and R.-S. Chang Coronary Arterial Calcification on Low-Dose Ungated MDCT for Lung Cancer Screening: Concordance Study with Dedicated Cardiac CT Am. J. Roentgenol., April 1, 2008; 190(4): 923 - 928. [Abstract] [Full Text] [PDF]

				A. Cristaudo, R. Foddis, A. Vivaldi, G. Guglielmi, N. Dipalma, R. Filiberti, M. Neri, M. Ceppi, M. Paganuzzi, G. P. Ivaldi, et al. Clinical Significance of Serum Mesothelin in Patients with Mesothelioma and Lung Cancer Clin. Cancer Res., September 1, 2007; 13(17): 5076 - 5081. [Abstract] [Full Text] [PDF]

				M. Kunnimalaiyaan and H. Chen Tumor Suppressor Role of Notch-1 Signaling in Neuroendocrine Tumors Oncologist, May 1, 2007; 12(5): 535 - 542. [Abstract] [Full Text] [PDF]